| 张炜,刘海青,骆桂法,金红宇,杨凤梅,刘亚蓉,张玉臣.佐太及珍宝类藏成药中汞在大鼠体内的蓄积研究[J].中国药事,2020,34(2):195-201 |
| 佐太及珍宝类藏成药中汞在大鼠体内的蓄积研究 |
| On Mercury Accumulation of Zuotai and Precious Tibetan Medicines in Rats |
| 投稿时间：2019-08-01 |
| DOI：10.16153/j.1002-7777.2020.02.008 |
| 中文关键词: 佐太 七十味珍珠丸 坐珠达西 汞 蓄积 |
| 英文关键词: Zuotai Qishiwei Zhenzhu Pill Zuozhudaxi mercury accumulation |
| 基金项目:青海省科技计划项目（编号2017-ZJ-Y40，2018-ZJ-T06） |
|
| 摘要点击次数: 1259 |
| 全文下载次数: 258 |
| 中文摘要: |
| 目的： 通过给SD大鼠灌胃服用不同剂量和不同时间的佐太及含佐太复方制剂，探索研究血液和主要器官中总汞和不同价态汞的蓄积情况，为临床用药提供参考依据。方法： 采用原子荧光法（光电倍增管负高压270 V，原子化器高度10 mm，载气流量400 mL·min-1，屏蔽气流量800 mL·min-1，灯电流20 mA）及高效液相色谱串联电感耦合等离子体质谱法（射频功率1420 W，射频电压1.79 V，载气体积流量1.10 L·min-1，蠕动泵流速0.1 r·s-1，氦反应碰撞模式，Hypersil gold C18色谱柱，柱温30℃，流动相为含0.06 mol·L-1乙酸铵和1 g·L-1半胱氨酸的5%甲醇-水溶液，流速1.0 mL·min-1）测定大鼠血清、血浆、全脑、肝脏、肾脏中总汞及甲基汞、乙基汞、无机汞的蓄积量。将60只SD大鼠随机分为空白组、佐太常剂量短期组（15 d，4.93 mg·kg-1）、常剂量长期组（30 d，4.93 mg·kg-1）、高剂量长期组（30 d，98.60 mg·kg-1）和2个复方制剂组（30 d，15.25~16.66 mg·kg-1），给药完成后测定大鼠血液和主要器官中总汞和不同价态汞的含有量。结果： 对照空白组结果，给予15 d常规剂量佐太后，血清、血浆、全脑和肝脏中总汞量有所增加，但无显著性差异，肾脏中总汞含量显著增加；给予30 d常规和高剂量佐太后，全脑、肝脏和肾脏中总汞含量显著增加，血清、血浆中总汞量有所增加，但无显著性差异；给予30 d常规剂量含佐太复方制剂后，肾脏中总汞含量显著增加，血液和其他器官无显著性差异。各组别大鼠血液和主要器官中以无机汞为主，血浆和肾脏中含有少量甲基汞，各部位均未检出乙基汞。结论： 大鼠灌胃给予佐太和含佐太珍宝类藏成药后，汞在肾脏、肝脏中和脑组织中产生蓄积，蓄积汞的形态多为二价无机汞，提示服用佐太及含佐太的珍宝类藏成药制剂时应控制剂量和服用周期。 |
| 英文摘要: |
| Objective: To explore the accumulation of total mercury and mercury of different valences in blood and major organs of rats and provide references for clinical medication after Zuotai and compound preparations containing Zuotai were orally administrated with different doses and duration. Methods: The atomic fluorescence method (photomultiplier tube negative pressure was 270 V, atomization device-height was 10 mm, the carrier flow was 400 mL·min-1, shielding gas flow was 800 mL·min-1, lamp current was 20 mA) and HPLC-ICP-MS (radio-frequency power was 1420 W, radio-frequency voltage was 1.79 V, the carrier flow was 1.10 L·min-1, peristaltic pump flow was 0.1 r·s-1 with Helium collision mode. The separation was performed on Hypersil gold C18 column with column temperature of 30℃ and mobile phase composed of 5% methanol aqueous solution containing 0.06 mol·L-1 ammonium acetate and 1 g·L-1 cysteine at the flow rate of 1.0 mL·min-1, the column temperature was at 30℃) were used to determine the accumulation of total mercury, methylmercury, ethyl mercury and inorganic mercury in serum, plasma, brain, liver, and kidneys of SD rats. 60 SD rats were randomly divided into the blank group, the short-term group of Zuotai conventional dose (15 d, 4.93 mg·kg-1), the longterm group of conventional dose (30 d, 4.93 mg·kg-1), the high-dose long-term group (30 d, 98.60 mg·kg-1) and two compound preparation groups (30 d, 15.25-16.66 mg·kg-1). The contents of total mercury and mercury of different valences in blood and major organs of rats were measured after administration. Results: Compared with the blank group, the content of total mercury in serum, plasma, brain and liver of rats in the short-term group of Zuotai conventional dose increased, but there was no significant difference. The content of total mercury in the kidneys increased significantly. The content of total mercury in the whole brain, liver and kidneys of rats in the long-term group of conventional dose and the high-dose long-term group significantly increased. The content of the total mercury in serum and plasma increased, but there was no significant difference. The content of total mercury in the kidneys of the rats in the two compound preparation groups significantly increased, and there was no significant difference in blood and other organs. Most of the mercury in the blood and major organs of rats in each group belonged to inorganic mercury. There was a small amount of methyl mercury in plasma and kidneys, and ethyl mercury was not detected in all parts. Conclusion: Mercury can be accumulated in kidneys, liver and brain of rats after Zuotai and the precious Tibetan medicines containing Zuotai are orally administrated. The main form of the accumulated mercury is divalent inorganic mercury, which suggests that the dose and duration should be controlled when Zuotai and the precious Tibetan medicines containing Zuotai are administarted. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|